These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20071982)

  • 21. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
    Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A
    Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
    Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eosinophilic myeloid neoplasms.
    Noel P; Mesa RA
    Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
    Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
    Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
    Tefferi A; Gotlib J; Pardanani A
    Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Review of changes introduced by the new WHO classification (4th edition) of myeloid neoplasms. An overview].
    Komatsu N
    Rinsho Ketsueki; 2009 Mar; 50(3):127-33. PubMed ID: 19352078
    [No Abstract]   [Full Text] [Related]  

  • 28. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia.
    Mattis DM; Wang SA; Lu CM
    Am J Clin Pathol; 2020 Aug; 154(3):305-318. PubMed ID: 32525541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Gotlib J
    Cancer Treat Res; 2008; 142():69-106. PubMed ID: 18283783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical myeloproliferative disorders: diagnosis and management.
    Tefferi A; Elliott MA; Pardanani A
    Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modern diagnosis and treatment of primary eosinophilia.
    Tefferi A
    Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.
    Gotlib J; Cools J
    Leukemia; 2008 Nov; 22(11):1999-2010. PubMed ID: 18843283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1].
    Fan XS; Wang SA
    Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):779-83. PubMed ID: 23302345
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease.
    Pardanani A; Verstovsek S
    Cancer J; 2007; 13(6):384-91. PubMed ID: 18032976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hypereosinophilic syndrome--difficult-to-catch diagnosis. Targeted molecular diagnostics and treatment now possible thanks to gene discovery].
    Jönsson S; Lewerin C; Jacobsson S; Wadenvik H
    Lakartidningen; 2006 Sep 6-12; 103(36):2556-9. PubMed ID: 17007200
    [No Abstract]   [Full Text] [Related]  

  • 38. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.
    Curtis CE; Grand FH; Musto P; Clark A; Murphy J; Perla G; Minervini MM; Stewart J; Reiter A; Cross NC
    Br J Haematol; 2007 Jul; 138(1):77-81. PubMed ID: 17555450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No asthma, no parasites is a rare type of leukemia: chronic myeloid neoplasm with eosinophilia and abnormality of platelet-derived growth factor receptor alpha.
    Santiago-Casiano M; Alemán JR; Matos-Fernández NA; Cáceres-Perkins W; De La Paz M
    Bol Asoc Med P R; 2012; 104(3):41-6. PubMed ID: 23156891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.